108 / 160
660
de 2011;8(11):610-34.
30. Cappell MS, Fox SR, Gorrepati N. Safety and efficacy of
colonoscopy during pregnancy: an analysis of pregnancy
outcome in 20 patients. J Reprod Med. marzo de 2010;55(3-
4):115-23.
31. Shergill AK, Ben-Menachem T, Chandrasekhara V, Chathadi
K, Decker GA, Evans JA, et al. Guidelines for endoscopy in
pregnant and lactating women. Gastrointest Endosc. julio de
2012;76(1):18–24.
32. Mahadevan U, Kane S. American Gastroenterological
Association Institute Technical Review on the Use of
Gastrointestinal Medications in Pregnancy. Gastroenterology.
julio de 2006;131(1):283–311.
33. Ooi BS, Remzi FH, Fazio VW. Turnbull-Blowhole colostomy for
toxic ulcerative colitis in pregnancy: report of two cases. Dis
Colon Rectum. enero de 2003;46(1):111-5.
34. Kane S, Lemieux N. The Role of Breastfeeding in Postpartum
Disease Activity in Women with Inflammatory Bowel Disease.
Am J Gastroenterol. enero de 2005;100(1):102-5.
35. Moffatt DC, Ilnyckyj A, Bernstein CN. A Population-Based Study
of Breastfeeding in Inflammatory Bowel Disease: Initiation,
Duration, and Effect on Disease in the Postpartum Period. Am J
Gastroenterol. 23 de junio de 2009;104(10):2517-23.
36. Matsui D. Adherence with Drug Therapy in Pregnancy. Obstetrics
and Gynecology International. 2012;2012(7419):1–5.
37. Julsgaard M, Nørgaard M, Hvas CL, Buck D, Christensen LA. Self-
reported adherence to medical treatment prior to and during
pregnancy among women with ulcerative colitis. Inflamm
Bowel Dis. 9 de diciembre de 2010;17(7):1573-80.
38. Argüelles-Arias F, Castro-Laria L, Barreiro-de Acosta M,
García-Sánchez MV, Guerrero-Jiménez P, Gómez-García MR,
et al. Is safety infliximb during pregnancy in patients with
inflammatory bowel disease? Rev Esp Enferm Dig. febrero de
2012;104(2):59–64.
39. Nørgård B, Czeizel AE, Rockenbauer M, Olsen J, Sørensen
HT. Population-based case control study of the safety of
sulfasalazine use during pregnancy. Aliment Pharmacol Ther.
abril de 2001;15(4):483-6.
40. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy
in inflammatory bowel disease: effect of sulfasalazine and
corticosteroids on fetal outcome. Gastroenterology. enero de
1981;80(1):72-6.
41. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H,
Bologa M, Pastuszak A, et al. The safety of mesalamine in
human pregnancy: a prospective controlled cohort study.
Gastroenterology. enero de 1998;114(1):23-8.
42. Hernández-Diaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R.
Medications as a Potential Source of Exposure to Phthalates in
the US Population. Environ Health Perspect. 2008.
43. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic
acid antagonists during pregnancy and the risk of birth defects.
N Engl J Med. 30 de noviembre de 2000;343(22):1608-14.
44. Klotz
U,
Harings-Kaim
A.
Negligible
excretion
of
5-aminosalicylic acid in breast milk. Lancet. 4 de septiembre
de 1993;342(8871):618-9.
45. Delaere KP, Strijbos WE, Meuleman EJ. Sulphasalazine-induced
reversible male infertility. Acta Urol Belg. 1989;57(1):29–33.
46. Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and
male infertility: reversibility and possible mechanism. Gut.
junio de 1981;22(6):445-51.
47. Zelissen PM, van Hattum J, Poen H, Scholten P, Gerritse R, Velde
te ER. Influence of salazosulphapyridine and 5-aminosalicylic
acid on seminal qualities and male sex hormones. Scand J
Gastroenterol. noviembre de 1988;23(9):1100-4.
48. Sartor RB. Therapeutic manipulation of the enteric microflora
in inflammatory bowel diseases: antibiotics, probiotics, and
prebiotics. Gastroenterology. mayo de 2004;126(6):1620-33.
49. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK,
et al. Antibiotic Therapy in Inflammatory Bowel Disease: A
Systematic Review and Meta-Analysis. Am J Gastroenterol. 15
de marzo de 2011;106(4):661-73.
50. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety
of metronidazole in pregnancy: a meta-analysis. American
Journal of Obstetrics and Gynecology. febrero de 1995;172(2
Pt 1):525-9.
51. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy
A. Pregnancy outcome after gestational exposure to
metronidazole: a prospective controlled cohort study.
Teratology. mayo de 2001;63(5):186-92.
52. Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE,
et al. Investigation of Metronidazole Use during Pregnancy
and Adverse Birth Outcomes. Antimicrobial Agents and
Chemotherapy. 17 de agosto de 2012;56(9):4800-5.
53. Passmore CM, McElnay JC, Rainey EA, D’Arcy PF. Metronidazole
excretion in human milk and its effect on the suckling neonate.
Br J Clin Pharmacol. julio de 1988;26(1):45–51.
54. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld
AE, et al. Pregnancy outcome following gestational exposure
to fluoroquinolones: a multicenter prospective controlled
study. Antimicrobial Agents and Chemotherapy. junio de
1998;42(6):1336-9.
55. Larsen H, Nielsen GL, Schønheyder HC, Olesen C, Sørensen HT.
Birth outcome following maternal use of fluoroquinolones. Int
J Antimicrob Agents. septiembre de 2001;18(3):259-62.
56. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML,
Gionchetti P. Rifaximin-Extended Intestinal Release Induces
Remission in Patients With Moderately Active Crohn’s Disease.
Gastroenterology. marzo de 2012;142(3):473-4.
57. Bay Bjørn A-M, Ehrenstein V, Holmager Hundborg H, Aagaard
Nohr E, Toft Sørensen H, Nørgaard M. Use of Corticosteroids in
Early Pregnancy is Not Associated With Risk of Oral Clefts and
Other Congenital Malformations in Offspring. Am J Ther. 24 de
septiembre de 2012.
58. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during
pregnancy and risk of orofacial clefts. CMAJ. 19 de abril de
2011;183(7):796–804.
59. Carmichael SL, Shaw GM. Maternal corticosteroid use and
risk of selected congenital anomalies. Am J Med Genet. 17 de
[REV. MED. CLIN. CONDES - 2015; 26(5) 649-662]